

VIGAFYDE - (100MG/1ML ; Solution)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | VIGABATRIN | Innovator | PYROS PHARMS |
| Dosage | 100MG/1ML ; Solution | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | VIGAFYDE is indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.